Quanterix Co. (NASDAQ:QTRX) Shares Acquired by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. increased its position in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) by 129.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 192,444 shares of the company's stock after buying an additional 108,503 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.50% of Quanterix worth $2,494,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Quanterix by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 2,069,423 shares of the company's stock valued at $48,756,000 after acquiring an additional 14,390 shares during the period. Lord Abbett & CO. LLC grew its holdings in Quanterix by 22.9% in the 1st quarter. Lord Abbett & CO. LLC now owns 1,757,153 shares of the company's stock worth $41,398,000 after acquiring an additional 326,876 shares during the last quarter. Easterly Investment Partners LLC raised its position in Quanterix by 779.9% during the 2nd quarter. Easterly Investment Partners LLC now owns 692,746 shares of the company's stock valued at $9,151,000 after purchasing an additional 614,012 shares during the last quarter. Baillie Gifford & Co. lifted its stake in Quanterix by 1.6% in the second quarter. Baillie Gifford & Co. now owns 633,460 shares of the company's stock worth $8,368,000 after acquiring an additional 10,105 shares during the period. Finally, Emerald Mutual Fund Advisers Trust boosted its stake in shares of Quanterix by 0.8% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 563,247 shares of the company's stock valued at $7,300,000 after purchasing an additional 4,406 shares in the last quarter. 86.48% of the stock is owned by institutional investors and hedge funds.

Quanterix Price Performance

QTRX stock traded up $0.67 during mid-day trading on Tuesday, reaching $14.52. The company had a trading volume of 390,231 shares, compared to its average volume of 395,765. The company has a market capitalization of $557.26 million, a PE ratio of -13.83 and a beta of 1.36. The firm has a 50 day moving average of $12.74 and a 200 day moving average of $14.05. Quanterix Co. has a 12 month low of $10.50 and a 12 month high of $29.70.

Quanterix (NASDAQ:QTRX - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The business had revenue of $34.38 million for the quarter, compared to analyst estimates of $34.19 million. Quanterix had a negative net margin of 30.71% and a negative return on equity of 11.52%. During the same period in the prior year, the company earned ($0.16) earnings per share. Analysts anticipate that Quanterix Co. will post -0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on QTRX. TD Cowen reduced their target price on shares of Quanterix from $17.00 to $15.00 and set a "hold" rating on the stock in a research report on Friday, August 9th. Scotiabank dropped their target price on Quanterix from $32.00 to $28.00 and set a "sector outperform" rating on the stock in a research report on Monday, August 12th. Finally, The Goldman Sachs Group reduced their price objective on Quanterix from $35.00 to $24.00 and set a "buy" rating for the company in a research note on Tuesday, July 9th.

Insider Buying and Selling

In other Quanterix news, Director David R. Walt bought 47,000 shares of the firm's stock in a transaction on Tuesday, August 20th. The shares were acquired at an average cost of $13.29 per share, with a total value of $624,630.00. Following the purchase, the director now directly owns 1,487,342 shares of the company's stock, valued at $19,766,775.18. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 6.90% of the stock is currently owned by insiders.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.